gout

Savient Pharmaceuticals: Is Anything Left?

Savient Pharmaceuticals: Is Anything Left?

Seeking Alpha

Savient Pharma: Still Struggling To Grow KRYSTEXXA Sales

Savient Pharma: Still Struggling To Grow KRYSTEXXA Sales

Seeking Alpha

Savient Receives Positive CHMP Opinion for Krystexxa Approval in the EU

Savient Receives Positive CHMP Opinion for Krystexxa Approval in the EU

Equities.com

FDA rejects expanded use of Regeneron drug for gout

FDA rejects expanded use of Regeneron drug for gout

Reuters

BioCryst jumps ahead of study presentation

BioCryst jumps ahead of study presentation

Marketwatch

Regeneron: FDA panel says no to Arcalyst for gout

Regeneron: FDA panel says no to Arcalyst for gout

Yahoo/AP

Myth Versus Reality: Promoting A Pricey Gout Pill

Myth Versus Reality: Promoting A Pricey Gout Pill

Pharmalot

Savient's Krystexxa: How I Get A $209 Million Sales Estimate By 2015

Savient's Krystexxa: How I Get A $209 Million Sales Estimate By 2015

Seeking Alpha

Savient Pharmaceuticals: The Potential Role Of Krystexxa The Treatment Of Gout

Savient Pharmaceuticals: The Potential Role Of Krystexxa The Treatment Of Gout

Seeking Alpha

Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity

Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity

Seeking Alpha